Curie Therapeutics

Curie Therapeutics is a biotechnology company focused on developing innovative radiopharmaceutical therapies for treating oncological diseases. The company takes an integrated approach to creating novel radiopharmaceutical drug candidates, optimized against various targets with high unmet medical needs across a wide range of solid tumors. Curie's approach involves bringing together expertise across radiobiology, radiochemistry, and cancer biology under one roof.

The company's technology platform is centered around rationally designing molecules and payloads optimized for the right target, patient, and dose. Curie is developing radiopharmaceuticals with different radiation particles, such as alpha and beta particles, depending on factors like tumor size. In addition to causing DNA damage in cancer cells, the company's radiopharmaceuticals aim to modulate tumor microenvironments in more subtle ways, such as inducing antigen expression, potentially enabling their use in treatment sequences or combinations with other therapies like immunotherapies or DNA damage repair inhibitors.

Curie's strategy involves integrating various disciplines, including ligand R&D, radiochemistry, translational sciences, and clinical development, to create optimized radiopharmaceutical molecules tailored for specific targets and indications. The company has appointed experienced executives with expertise in radiopharmaceutical development, such as Bernard Lambert, Ph.D. (Chief Technology Officer), and Kapil Dhingra, MBBS (Board of Directors), to support its mission.